I spoke with Rob Goldman earlier about the upcoming trials and the $$$ needed to go to Trials and get completion. Here is part of his take on the whole issue:
"I would be shocked if they have $ issues for this trial. They will have it. It does not take billions to develop a drug and get it approved. It would take many tens of millions, however. This trial should not cost more than $4-5 million, based on the design. It just takes time for the protocol to be completed, getting ducks in a row and meeting with the FDA prior to submission. My guess is that they're are in the 6th inning of all this. That FDA meeting is the next big trigger for the stock to move back to previous, higher ranges. Then we have the launch, followed by the release of interim data (after a few months). Better to dot "I's" and cross "T's" and make sure they get it right."
Market Data 
Markets 
AI
